Short answer
ResMed (RMD) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 announces ResMed’s operating results for the quarter ended September 30, 2026.
ResMed 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Exhibit 99.1 announces ResMed’s operating results for the quarter ended September 30, 2026
- Investors should review the accompanying release for revenue, earnings, margins, guidance and business drivers
Item 8.01 · Other Events
- Quarterly cash dividend of $0.66 per share declared, signaling continued shareholder distributions
- November 12, 2026 record date, with payment scheduled for December 17, 2026
- November 11, 2026 ex-dividend date for NYSE shares and ASX-traded CDIs
- CDI holders receive equivalent Australian-currency payment, reflecting the 10:1 CDI-to-share ratio
Item EX-99.1 · Exhibit EX-99.1
- Q1 FY2027 revenue $1.415B, up 6%, with core constant-currency growth of 7% driven by sleep devices and masks
- GAAP diluted EPS $2.92, up 23%; non-GAAP EPS $2.91, up 14%, supported by stronger gross margin
- Non-GAAP gross margin expanded 50 basis points to 62.5%, while operating margin declined 30 basis points to 35.8%
- MatrixCare divestiture closed, generating $450.8M proceeds and sharpening focus on sleep and breathing health
- Shareholder returns exceeded $1.0B through repurchases and dividends, including a declared $0.66 quarterly dividend
- FY2027 guidance unchanged: reported revenue $5.75B-$5.85B and non-GAAP EPS $12.00-$12.25
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ResMed 8-K filings
Get the next RMD 8-K as it lands
Follow RMD for push alerts, or ask the research agent what this filing means.